Ildong Pharmaceutical said Wednesday it released a new hyaluronic acid filler Hyaleve Series and began full-scale marketing.Hyaleve Series is a medical device for tissue repair and wrinkle improvement. The treatment contains a non-animal and sterile hyaluronic acid derivative, which was obtained thr
RedHill Biopharma, an Israel-based biopharmaceutical firm, said Wednesday that it signed an exclusive license agreement with Kukbo, a Korean company, for opaganib, an oral Covid-19 treatment.Under the agreement, RedHill will receive a $1.5 upfront payment and up to $5.6 million in milestone payments
SK Bioscience said it submitted a rolling review document for the rapid approval of the GBP510, its Covid-19 vaccine candidate, to U.K.'s Medicines and Healthcare products Regulatory Agency (MHRA).The company aims to go through the sequential screening stage and proceed to the final evaluation as qu
After six years of conducting post-market surveillance (PMS) for Janssen Korea's prostate cancer treatment Zytiga (ingredient: abiraterone acetate), the Ministry of Food and Drug Safety confirmed an adverse event incidence rate of 34.98 percent.The PMS on 626 patients found five cases of serious adv
Elevar Therapeutics, the U.S. subsidiary of HLB, said on Tuesday it appointed Dr. Chong Sae-ho and Dr. Jang Seong-hoon, former clinical pharmacologists at the FDA, as new CEO and chief operating officer (COO).Chong, appointed as CEO, received his Ph.D. in Pharmaceutics at the School of Pharmacy of t
Hutecs Korea and Daewoong Pharmaceutical topped the list of drugmakers with the largest number of clinical trial approvals by the Ministry of Food and Drug Safety this year.On Tuesday, the ministry said that it approved 192 clinical trials this year, including termination reports and excluding contr
The contract manufacturing organization (CMO) businesses concerning the Covid-19 vaccine undertaken by Korean pharmaceutical companies are showing mixed results.While the subsidiaries of large conglomerates, such as Samsung Biologics and SK Bioscience, are manufacturing Covid-19 vaccines, independen
Lilly Korea said the Ministry of Food and Drug Safety approved its Retevmo 40mg and 80mg as Korea's first RET (Rearranged during Transfection) inhibitor treatment on Friday.Under the approval, hospitals can use Retevmo in treating adult patients with metastatic RET fusion-positive non-small cell lun
Genexine said it would halt developing GX-19N, a Covid-19 vaccine candidate. The termination of the two-year pipeline development is expected to bring considerable repercussions such as financial losses and unhappy reactions from the company’s shareholders, industry watchers said.In a public disclos
MSD’s Keytruda (ingredient: pembrolizumab) became a new treatment option for metastatic esophageal or gastroesophageal junction (GEJ) carcinomas that had no first-line therapy for decades.On Monday, the Ministry of Food and Drug Safety granted Keytruda’s additional indication for the first-line trea
Huons Global announced ending the contract manufacturing organization (CMO) deal over Russia’s Covid-19 vaccine, Sputnik V.Prestige Biopharma, a member of Huons Global’s consortium for Sputnik V manufacturing, said it received such notification from Huons Global on the day of the deal termination an
Amgen Korea, which had conquered Korea's osteoporosis treatment market with Prolia and Evenity, set a new milestone last year by becoming the first company to surpass 100 billion won ($81.3 million) in annual sales.According to IQVIA, a drug market research company, sales of Prolia's (ingredient: de
Roche is negotiating with the government over the reimbursement price of Tecentriq (atezolizumab), which passed the review of the Health Insurance Review and Assessment Service (HIRA) in January.Depending on the result, the use of Avastin (bevacizumab) in combination with Tecentriq in liver cancer c
Hanmi Pharmaceutical said the company would market its blockbuster hypertension drug Amosartan in China, making it the first homegrown combination therapy to enter the Chinese blood pressure treatment market.Beijing Hanmi Pharmaceutical received market approval for the treatment from China's Nationa
Celltrion said it would locally manage the entire manufacturing process for Remsima SC (infliximab), a biosimilar referencing Remicade, to reduce the production time from contract manufacturing overseas.On Monday, Celltrion obtained local approval for Celltrion Remsima Pre-filled Syringe Inj. 120mg,
A three-university research team has successfully synthesized a nanozyme and used it to develop a paper-based disease substance detection sensor, which can detect six target substances simultaneously.Enzymes act as catalysts for various chemical reactions in a person’s body. Still, recently, reports
Pharma Essentia Korea said that the U.S. National Comprehensive Cancer Network (NCCN) guidelines have updated Besremi (Ingredient: ropeginterferon alfa-2b) as a recommended option for the treatment of polycythemia vera (PV).According to the company, Besremi is the only first-line treatment and next-
Korea United Pharm is seeking to expand the indication of Clanza CR (ingredient: aceclofenac), an incrementally modified drug (IMD) for relieving pain in various diseases.On Tuesday, the company said it began a clinical trial of Clanza CR to add an indication for “post-traumatic pain.”Clanza CR’s au
Yuhan Corp. said it canceled a licensing deal with Imnewrun Biosciences over brain disease treatment candidates.In a public filing on Tuesday, Yuhan said it terminated the agreement with Imnewrun signed on Feb. 19, 2020, intended for technology introduction and joint R&D of three brain disease drug
Sanofi’s nirsevimab, the first long-acting antibody that prevents respiratory syncytial virus (RSV) in infants just with a single administration, proved it could reduce the incidence of lower respiratory tract infection (LRTI) in phase 3 clinical trial. The results indicate that it could be in the f